Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 FacebookTwitterPinterestEmail previous post Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation next post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis You may also like Summit Royalties Announces Agreement to Acquire Royalty on Newmont’s... March 12, 2026 Syntholene Selects Papadakis Engineering as Integration Partner for... March 12, 2026 Lahontan Announces Private Placement March 12, 2026 Harvest Gold Expands Its Mosseau Property Along Strike... March 12, 2026 CHARBONE presentera a la conference Hydrogen East et... March 12, 2026 Tartisan Nickel Corp. Intersects 24.6 Metres of 0.71%... March 12, 2026 LaFleur Minerals Inc.Taking Key Steps to Advance Position... March 12, 2026 NevGold Mobilizes Drill To Test Historical Leach Pads... March 12, 2026 Cartier Cuts 7.1 g/t Au over 8.0 m... March 12, 2026 Silver Stocks: 5 Biggest Silver-mining Companies in 2026 March 11, 2026